(0.34%) 5 117.07 points
(0.33%) 38 367 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.25%) $2.02
(0.34%) $2 355.10
(0.52%) $27.68
(4.12%) $960.05
(-0.28%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States...
Stats | |
---|---|
本日の出来高 | 372 349 |
平均出来高 | 105 224 |
時価総額 | 380.11M |
EPS | $0 ( 2024-03-04 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.07 |
ATR14 | $0.0590 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-24 | Secor Alicia | Sell | 46 000 | Stock Option (Right to Buy) |
2024-01-24 | Secor Alicia | Sell | 105 000 | Stock Option (Right to Buy) |
2024-01-24 | Geraghty James A | Sell | 44 391 | Ordinary Shares |
2024-01-24 | Geraghty James A | Sell | 46 000 | Stock Option (Right to Buy) |
2024-01-24 | Geraghty James A | Sell | 105 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-31.90 |
Last 99 transactions |
Buy: 13 341 271 | Sell: 6 351 136 |
ボリューム 相関
Orchard Therapeutics PLC 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Orchard Therapeutics PLC 相関 - 通貨/商品
Orchard Therapeutics PLC 財務諸表
Annual | 2022 |
収益: | $6.99M |
総利益: | $4.55M (65.17 %) |
EPS: | $-0.610 |
FY | 2022 |
収益: | $6.99M |
総利益: | $4.55M (65.17 %) |
EPS: | $-0.610 |
FY | 2021 |
収益: | $1.68M |
総利益: | $1.45M (86.51 %) |
EPS: | $-1.170 |
FY | 2020 |
収益: | $2.60M |
総利益: | $1.74M (66.97 %) |
EPS: | $-1.530 |
Financial Reports:
No articles found.
Orchard Therapeutics PLC
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。